Horizon Scanning

It is a challenge for health plans and clinicians to know what emerging technologies are in the preapproval phase and what their clinical, financial, and risk impacts might be. This is where we come in.

The Hayes Horizon Scanning Solution identifies innovative and potentially disruptive health technologies that are in various stages of the regulatory approval process. Our Research Analysts continually investigate new technologies that are on the horizon or in the early stages of clinical investigation, as well as the testing of existing technologies that may be seeking approval for new clinical applications. Hayes Horizon Scanning helps you track emerging technologies before you need to make decisions. Accessed through the Hayes Knowledge Center, Hayes Horizon Scanning addresses the following fundamental questions to help our clients forecast emerging technologies:

  • Is this emerging technology new or replacing an existing technology?
  • Where is this technology in the FDA regulatory process?
  • When will this technology be commercially available in the market?
  • What is the projected use, cost, and financial impact of this technology?

Idraparinux

A subcutaneously administered anticoagulant for the treatment and secondary prevention of thromboembolism in patients with acute, symptomatic, deep vein thrombosis or pulmonary embolism.

Arzoxifene

An oral selective estrogen receptor modulator for prevention and treatment of osteoporosis in postmenopausal women.

Multaq® (Dronedarone)

An oral, multichannel blocking, antiarrhythmic drug being developed for the management of atrial fibrillation or atrial flutter. 

Dirucotide

An intravenous drug for the treatment of secondary-progressive multiple sclerosis.